8-K current report · filed Oct 7, 2026

Spyre Therapeutics, Inc. (SYRE) 8-K Current Report: October 7, 2026

Item 1.01SYRE overview

Short answer

Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on October 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $350.0 million gross equity raise at $85.00 per share, strengthening Spyre’s funding runway.

Spyre Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $350.0 million gross equity raise at $85.00 per share, strengthening Spyre’s funding runway
  • Potential additional 617,647 shares through the 30-day underwriter option, creating further dilution risk
  • Proceeds targeted to Gastroenterology, Rheumatology, Dermatology and SPY072 late-stage development
  • Funding supports preclinical studies, clinical trials, manufacturing and Phase 3 readiness
  • Expected closing October 7, 2026, subject to customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Spyre Therapeutics, Inc. 8-K filings

Get the next SYRE 8-K as it lands

Follow SYRE for push alerts, or ask the research agent what this filing means.